{
    "clinical_study": {
        "@rank": "159778", 
        "arm_group": [
            {
                "arm_group_label": "Arm N - Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
            }, 
            {
                "arm_group_label": "Arm N-I: Nivolumab+Ipilimumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg solution  every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the safety and efficacy of Nivolumab as a single agent or in combination with\n      Ipilimumab in 4 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC),\n      pancreatic adenocarcinoma (PC), and small cell lung cancer (SCLC)"
        }, 
        "brief_title": "A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced or Metastatic Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects with histologically confirmed locally advanced or metastatic disease of the\n             following tumor types:\n\n          -  Triple Negative Breast Cancer\n\n          -  Gastric Cancer\n\n          -  Pancreatic Cancer\n\n          -  Small Cell Lung Cancer\n\n          -  Subjects must have measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases\n\n          -  Subjects with active, known or suspected autoimmune disease\n\n          -  Subjects with a condition requiring systemic treatment with either corticosteroids\n             (>10 mg daily prednisone equivalents) or other immunosuppressive medications within\n             14 days of treatment\n\n          -  Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or\n             checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or\n             anti-CTLA-4 antibody, including Ipilimumab; or other medicines specifically targeting\n             T cell is also prohibited"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "218", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928394", 
            "org_study_id": "CA209-032", 
            "secondary_id": "2013-002844-10"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm N - Nivolumab", 
                    "Arm N-I: Nivolumab+Ipilimumab"
                ], 
                "intervention_name": "Nivolumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "BMS-936558", 
                    "MDX-1106"
                ]
            }, 
            {
                "arm_group_label": "Arm N-I: Nivolumab+Ipilimumab", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Yervoy", 
                    "BMS-734016", 
                    "MDX-010"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Joseph Eder, Site 0015", 
                    "phone": "203-785-5702"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Scott Antonia, Site 0021"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Inst, Inc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rathi Pillai, Site 0001", 
                    "phone": "404-712-7485"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Winship Cancer Institute, Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dung Le, Site 0004", 
                    "phone": "443-287-6122"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrick Ott, Site 0005", 
                    "phone": "617-582-7545"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Margaret Callahan, Site 0006", 
                    "phone": "646-888-3359"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Asim Amin, Site 0003", 
                    "phone": "980-442-2305"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "Levine Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Morse, Site 0008", 
                    "phone": "919-668-6406"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Matthew Taylor, Site 0007", 
                    "phone": "503-494-1080"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Johanna Bendell, Site 0011", 
                    "phone": "615-329-7450"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology Pllc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Emily Chan, Site 0002", 
                    "phone": "615-343-0798"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Ctr"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Padmanee Sharma, Site 0009", 
                    "phone": "713-563-1602"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "The University Of Texas Md Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0014"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00029"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0019"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0020"
                }, 
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0017"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0010"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0018"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "Greater London", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0012"
                }, 
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "state": "Lanarkshire", 
                        "zip": "G12 0YN"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0013"
                }, 
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Finland", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Finland: Finnish Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Italy: Ministry of Health", 
                "Italy: National Bioethics Committee", 
                "Italy: National Institute of Health", 
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ministry of Health", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR is defined as the number of subjects with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of assigned subjects", 
            "measure": "Objective response rate (ORR) in all assigned subjects as determined by the investigators", 
            "safety_issue": "No", 
            "time_frame": "Up until time of first documented tumor progression or death (approximately up to 17 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928394"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Rate of treatment-related adverse events (AEs) leading to drug discontinuations during the first 12 weeks of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Week 12 of treatment"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}